Abstract
AbstractIn vitro dissolution generally involves sink conditions, so dissolution equations generally do not need to accommodate non-sink conditions. Greater use of biorelevant media, which are typically less able to provide sink conditions than pharmaceutical surfactants, necessitates equations that accommodate non-sink conditions. One objective was to derive an integrated, one-parameter dissolution equation for percent dissolved versus time that accommodates non-sink effects via drug solubility and dissolution volume parameters, including incomplete solubility. A second objective was to characterize the novel equation by fitting it to biorelevant dissolution profiles of tablets of two poorly water-soluble drugs, as well as by conducting simulations of the effect of dose on dissolution profile. The Polli dissolution equation was derived, $$\% \;dissolved=100\%\left[1-\frac{\left({{M}_{0}-c}_{s}V\right)}{{M}_{0}-{{c}_{s}Ve}^{{-k}_{d}\left(\frac{{{M}_{0}-c}_{s}V}{V}\right)t}}\right]$$
%
d
i
s
s
o
l
v
e
d
=
100
%
1
-
M
0
-
c
s
V
M
0
-
c
s
V
e
-
k
d
M
0
-
c
s
V
V
t
, where M0 is the drug dose (mg), cs is drug solubility (mg/ml), V is dissolution volume (ml), and kd is dissolution rate coefficient (ml/mg per min). Maximum allowable percent dissolved was determined by drug solubility and not a fitted extent of dissolution parameter. The equation fit tablet profiles in the presence and absence of sink conditions, using a single fitted parameter, kd, and where solubility ranged over a 1000-fold range. kd was generally smaller when cs was larger. FeSSGF provided relatively small kd values, reflecting FeSSGF colloids are large and slowly diffusing. Simulations showed impact of non-sink conditions, as well as plausible kd values for various cs scenarios, in agreement with observed kd values. The equation has advantages over first-order and z-factor dissolution rate equations. An Excel file for regression is provided.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Food and Drug Administration. Dissolution testing of immediate release solid oral dosage forms. 1997. https://www.fda.gov/media/70936/download. Accessed 18 Aug 2022.
2. United States Pharmacopeial Convention Committee of Revision. United States pharmacopeia - national formulary 2022. Rockville, MD: United States Pharmacopeial Convention; 2022.
3. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285:135–46. https://doi.org/10.1016/j.ijpharm.2004.08.001.
4. Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013;453:12–24. https://doi.org/10.1016/j.ijpharm.2013.04.044.
5. Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci. 1997;86:690–700. https://doi.org/10.1021/js960473x.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献